Deregistration of medicinal products
The deadline for deregistration of medicinal products (not packages) depends on whether the marketing authorisation holder or a representative has access to DKMAnet.
In general, requests for deregistration of medicinal products can be submitted throughout the year. However, if companies want to avoid paying the annual fee for a medicinal product for the subsequent year, deregistration must be done in time before year-end.
If the medicinal product is still registered on the first day of a new year, the annual fee will be charged for the entire year, regardless of what time of the year it is deregistered.
Deregistration via DKMAnet
Requests for deregistration must be submitted via DKMAnet no later than two weeks before the deregistration is to take effect.
Submission deadline for deregistrations via DKMAnet
To make sure that deregistration of medicinal products takes place before 1 January 2024, your deregistration request must be submitted to us by Monday 11 December 2023 at 20:00. If we receive your request in time, deregistration of the concerned medicinal product will take effect on 25 December 2023.
Deregistrations which are to take effect on 25 December 2023 can be submitted via DKMAnet from Monday 27 november 2023 at 20:00 to Monday 11 December 2023 at 20:00.
Other deregistrations
Withdrawal of Marketing Authorisations can be done using DKMAnet or by writing to the Danish Medicines Agency. Letters concerning Marketing Authorisation withdrawals must reach the Danish Medicines Agency no later than 11 December 2023, to ensure the product(s) are deregistered before the 1 January 2024.
Special duty to notify medicine supply difficulties
If the deregistration of a medicinal product could lead to serious supply difficulties, the holder of the marketing authorisation must notify the Danish Medicines Agency separately by sending an email to this link – in addition to making the actual deregistration of the product. You can read more about the notification duty on the webpage: Serious medicine supply difficulties.